On August 27, 2025 Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, reported that the Company’s CEO, Gil Efron will participate in a fireside chat and 1×1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025 (Press release, Purple Biotech, AUG 27, 2025, View Source;id=362152&p=2397977&I=1206939-c7Z3G6f3m8 [SID1234655523]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are as follows:

H.C. Wainwright 27th Annual Global Investment Conference

Format: Fireside Chat
Date: Wednesday, September 10, 2025
Time: 11:30 AM ET

Management will be holding 1 x 1 meetings as well. Please schedule through the H.C. Wainwright conference portal.